Dream big with Zelira, page-681

Great points Dave.

This is why I am still buying them. ZLD is a dog of the market at the moment. Lots of other stocks are out performing it. But, it is sticking to its strategy, of developing a clinicly tested pipeline, and aiming at worldwide distribution. The pipeline is based around the most common medical conditions for which cannabis medicine is used. The potential customer base is huge. The 10% to 15% royalty will be huge.

A slow burner, but if they accomplish what they say they will, this will fly. But patience still needed for the medium term.

The share price will probably wallow until a few 4Cs prove otherwise. But if they get a Pain, Insomnia and Autism (also being used for anxiety in the states) formulations selling globally the rest of the pipeline will be money for jam.

Will the end game be a buy out? Or will ZLD stay on point and provide a dividend? A long way in the future, but interesting to ponder.